Role fibrosis markers to stratify risk of atrial fibrillation in patients with arterial hypertension and ekstakardialnoy pathology
https://doi.org/10.25694/URMJ.2018.12.27
Abstract
The aim of the study was to study the role of fibrosis markers (galectin - 3 and NT-proBNP) in stratification of atrial fibrillation risk in patients with arterial hypertension in combination with extracardial diseases. Materials and methods. In a prospective cohort study, 140 men aged 35-65 years with hypertension and AF (paroxysmal and persistent form), 57 - AH, AF and chronic obstructive pulmonary disease (COPD) and 83 patients with hypertension, AF without comorbidity (control) were observed. Serum galectin-3 and NT-proBNP levels were assessed by enzyme immunoassay. Anthropometry, lipid spectrum and Echocardiography studies were performed for all examined patients. Results. The level of galectin-3 in blood serum of patients with AF and COPD was higher-36.02 ng / ml. than in the control group-19.23 ng / ml, p=0.001. The average level of NT-proBNP in all the study group was significantly higher and amounted to 123.8 PG / ml, p<0.001, compared with the control group 67.99 PG / ml. Conclusion. Markers of fibrosis galectin-3 and NT-proBNP in serum of patients with atrial fibrillation and arterial hypertension in combination with chronic obstructive pulmonary disease are higher than in patients with atrial fibrillation and arterial hypertension
About the Authors
L. D. Khidirova
ГБОУ ВПО Новосибирский государственный медицинский университет Минздрава России; Новосибирский Областной Кардиологический Клинический Диспансер
Russian Federation
Russian Federation
D. A. Yakhontov
ГБОУ ВПО Новосибирский государственный медицинский университет Минздрава России; Новосибирский Областной Кардиологический Клинический Диспансер
Russian Federation
Russian Federation
S. A. Zenin
ГБОУ ВПО Новосибирский государственный медицинский университет Минздрава России; Новосибирский Областной Кардиологический Клинический Диспансер
Russian Federation
Russian Federation
References
1. Savelieva I, Camm J. Update on atrial fibrillation: part I. Clin. Cardiol. 2008; 31(2): 55-62.
2. De Boer R.A. et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011; 43(1): 60-68.
3. Jennifer E.H. et al. Galectin 3 and incident atrial fibrillation in the community. Am. Heart J. 2014; 167: 729-734.
4. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythmia Electrophysiol. 2008; 1(1): 62-73.
5. Menezes A.R., Lavie C.J., Di Nicolantonio J.J. Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies. Mayo Clin Proc. 2013; 88(4): 394-409.
6. Akoum N, Marrouche N. Assessment and impact of cardiac fibrosis on atrial fibrillation. Curr Cardiol Rep. 2014; 16(8): 518.
7. Beinart R et al. Сardiac magnetic resonance T1 mapping of left atrial myocardium. Heart Rhythm. 2013; 10(9): 1325-1331.
8. Weber KT et al. Aldosteronism in heart failure: a proinflammatory / fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr Drug Targets. 2003; 4(6): 505-516.
9. Earlings L.W., Sanders-van Wijk S., van Kraaij D.J. et al. Riskstrati fication with the use of serial N-terminal-pro-B-Type Natriuretic Peptide Measurments During admission and early after dischargein heart failure patients: post hoc analysis of the PRIMA Study // J. Cardiac. Fail. 2014. V. 20. P. 881-890. https://DOI.org/10.1093/eurheartj/ehs104
10. Troughton R.W., Frampton C.M., Brunner-La Rocca H.P. et al. Effectof B-type natriuretic peptide-guided treatment of chronic heartfailu re on total mortality and hospitalization: an individual patientmeta-analysis // Eur. Heart J. 2014. V. 35. P. 1559-1567. DOI: 10.21037/jxym.2017.12.02
11. Lok D.J., Lok S.I., Bruggink-Andre de la Porte P. W. et al. Galectin-3is an independent marker for ventricular remodeling and mortalityin patients with chronic heart failure // Clin. Res. Cardiol. 2013.102. P. 103-110. DOI: 10.1007/s10557-014-6520-2
12. Otzturk D., Celik O., Satilmis S. et al. Association between serumgalectin-3 levels and coronary atherosclerosis and plaque burden / structure in patients with type 2 diabetes mellitus // Coron.Artery Dis. 2015. [Epub. ahead of print]. http://dx.DOI.org/10.1097/MCA.0000000000000252
13. Yalcin M.U. et al. The association of serum galectin-3 levels with atrial electrical and structural remodeling. J Cardiovasc Electrophysiol. 2015;
Review
For citations:
Khidirova LD, Yakhontov DA, Zenin SA. Role fibrosis markers to stratify risk of atrial fibrillation in patients with arterial hypertension and ekstakardialnoy pathology. Ural Medical Journal. 2018;(12):165-169. (In Russ.) https://doi.org/10.25694/URMJ.2018.12.27
Views:
133
Email this article 